Christine Sagen Helgø
Mayor of Stavanger
Christine Sagen Helgø has been the mayor of Stavanger since the regional election of October 17th, 2011. Sagen Helgø represents the Conservative Party of Norway, Høyre. She has seen almost 18 years of Stavanger’s politics. Christine Sagen Helgø has been a member of the City Council in Stavanger from 1999, group leader for the Conservative Party from 2003-2011 and head of the municipal committee for urban development in Stavanger from 2007-2011. Sagen Helgø is also the president of the World Energy Cities group for the 2014-2016 term.
Rector, University of Stavanger
Since 2011, Marit Boyesen has served as Rector of the University of Stavanger (UiS).
She graduated with a PhD in sociology in addition to teacher training. Boyesen also has experience as a teacher, researcher, and assistant professor.
She was an associate professor at the Faculty of Economy, Culture and Social Sciences, at the University of Stavanger.
In 2004, she was Dean of the Faculty of Social Science at the University of Stavanger. From 2003-2007 she was in the Executive Board of the Research Council. Boyesen has also held a number of positions in research and higher education.
Associate Professor, Department of Strategy at BI Norwegian Business School
Thomas Hoholm is a Associate Professor at the Department of Strategy at BI Norwegian Business School. His research areas are managing and organizing innovation, learning and knowledge in and across organizations. Studies of the food industry (agri- and aquaculture), and of healthcare technologies and practices. Particularly interested in how organizational and market practices and processes tend to be shaped through a complex interplay of human, technological, economic and cultural elements.
PhD, Senior Researcher, Institute for Energy Technology / OECD Halden Reactor Project
István Szőke is a Senior Researcher at Institute for Energy Technology/OECD Halden Reactor Project. He has primarily been involved in theoretical developments such as simulation of biophysical processes, e.g biological effects of inhaled radionuclides and deterministic radiation transport. He has also had experience with technical developments, particularly computer programming. This to improve safety through a better assessment and presentation of risks to humans and the environment. He has also researched into the health effects of low-doses of inhaled radio-nuclides by means of biophysical modelling.
Currently, István’s main focus within the field is researching concepts and developments of support systems based on 3D simulations, virtual reality, and advanced user interface technology. The goal is to improve safety and efficiency of nuclear decommissioning projects.
Jonathan G. Lasch
PhD Executive Director of the Alfred E. Mann Institute for Biomedical Engineering
Dr. Jonathan G. Lasch is the Executive Director for the Alfred E. Mann Institute for Biomedical Engineering at the University of Southern California (AMI-USC). He brings more than 30 years of experience in science and technology development and evaluation in the fields of biomedical instruments and systems, biotechnology, chemistry, and materials science. Jon is a Research Professor of Biomedical Engineering in the Viterbi School of Engineering and a Professor of Clinical Entrepreneurship in the Greif Center of the Marshall School of Business at USC. Prior to joining AMI-USC, he served as a Managing Director of Convergent Ventures (CV), an early stage life sciences venture investment and development company. While at CV, he served on the boards of directors and/or as CEO of Neurion Pharmaceuticals, Inc., ORFID Corporation, and Encode Bio, Inc. Currently, Jon serves on the board of directors of several local development stage life sciences companies.
Dr. Lasch received his Bachelor of Science degree in Biological Science from the University of Texas at El Paso and his PhD in Chemistry from the University of Texas at Austin, and is a Fellow of the American Institute for Medical and Biological Engineering
David Horn Solomon
Managing Partner, Sund Capital
Dr. David Horn Solomon studied medicine and immunology at Cornell Medical College and the Sloan Kettering Cancer Center in New York City, where he received his doctorate in 1991. Dr. Solomon is currently the Managing Partner at Sund Capital in Copenhagen. He has also served as CEO of Zealand Pharma A/S and Bionor ASA both publicly listed healthcare companies as well as a Board Member in public companies. Dr. Solomon has an extensive experience in pharmacology research as a professor at Columbia University and more than 20 years of combined experience in medical research, healthcare investing and key biopharmaceutical & medical device operating roles. Dr. Solomon has also taught and lectured extensively at institutions around the world.
Director of Investment Banking, Leerink
Gabriel Cavazos joined Leerink in 2008. He is responsible for Biopharma coverage in the U.S. and Europe. Transactional experience balanced 50 / 50 between M&A and financial advisory. Cavazos previously worked at J.P. Morgan in the Mergers & Acquisitions group in New York. Prior to J.P. Morgan, he spent eight years in the pharmaceutical industry at Merck and Pfizer. Gabriel received his M.B.A. from the Kellogg School of Management at Northwestern University and a B.S. from The University of Michigan
eHealth Unit Leader Nordics, IBM Denmark
Birgitta Tunning works for IBM Denmark as eHealth Unit Leader for the Nordic region. She is responsible for IBM’s eHealth-solutions for healthcare and life-science entities in the Nordic countries.
Earlier in her IBM career Birgitta was a cross industry Sales Director for a number of years. Tunning holds an MBA in Strategic Planning & International Marketing/Business-to-Business Marketing from Copenhagen Business School (CBS).
Investment Manager, GlenRock Israel
Asaf is GlenRock’s Investment Manager and sits on the Board of Directors of several public and private companies. Prior to joining GlenRock, Asaf worked as a consultant for MATI, a public organization committed to assisting the establishment and expansion of businesses, providing business planning for startups and existing businesses, and advising entrepreneurs about establishing businesses. Previously, Asaf worked at Meitar Liquornik Geva & Leshem Brandwein Law Offices. Additionally, Asaf was involved in several independent entrepreneurial ventures. From 2006 Asaf has been scouting and leading investments in GlenRock. Working closely with the portfolio companies, taking board observer and board member seats, and providing consulting to companies’ management.
Asaf holds an Executive MBA, an MA in Philosophy, an L.L.B and a B.A. degree in Management.
Nathalie ter Wengel
European Head External R&D and Innovation of Pfizer
Nathalie ter Wengel is a Medical Doctor and the European Head of External Science and Innovation at Pfizer. Nathalie is responsible for establishing new collaborations and exploring licensing and other corporate development opportunities across all therapeutic areas in Europe. She has a broad knowledge of the medical field, having studied Internal Medicine. Nathalie started her commercial career at Pfizer as European Medical Manager where she successfully led ambitious international projects. It was this experience, coupled with her father’s illness, that convinced her of the urgent need for change in the pharmaceutical industry. coupled Consequently, she started up a company called myTomorrows focused on compassionate use, and served as Chief Medical Officer before joining Galapagos as Business Development Director, where she played a key role in the very successful NASDAQ IPO and in partnering filgotinib.
Egil Utheim is founder of Mektron AS, a company offering robotics for industrial and health applications.
Mr Egil is an entrepreneur having more than 20 years experience as an engineer and manager within the fields of robotics and automation and health technologies. He focuses on enabling elderly and disabled people to live better lives assisted by robotics and self motivating applications.
Head of Operations of SynerLeap, ABB
Gaetana Sapienza holds a Ph.D. degree in hardware/software design methodology for embedded systems applications from Mälardalen University, Sweden (2016) and received a M.Sc. degree in Computer Science Engineering (2007) from the University of Catania, Italy. Since 2016, she is the Head of Operations of SynerLeap powered by ABB, an innovation growth hub located at ABB Corporate Research Center, Sweden. She joined ABB in 2006, and worked in different R&D positions and international projects, currently she is working as senior scientist at ABB Corporate Research Center, Sweden.
Thomas F. Anglero
Director of Innovation, IBM Norway
Thomas F. Anglero is Director of Innovation for IBM Norway responsible for IBM Watson and innovation projects with all IBM customers. Thomas is the creator of the new and exciting Watson Innovation Lab at the Oslo Cancer Cluster (OCC) which is the home of Watson for the Nordic countries. Prior to IBM, Thomas was the Director of Innovation for Skatteetaten (Norwegian Tax Authorities). Thomas has over 25 years of global IT and Telecom experience including starting startups. Thomas is also a social entrepreneur and has helped many people all over the world. He continues to teach to Norwegian students on passion, leadership and dignity.
Managing Partner, Aleap
Erling has been a leader in the global life science industry for more than 18 years, with experience spanning from large pharmaceutical companies to small biotech startups. Before starting up Aleap, Erling was General Manager in Shire Human Genetic Therapies, a company developing, manufacturing and marketing orphan drugs for rare diseases. Erling has also worked with a large range of Norwegian life science startups. Erling holds a Master’s in Business Administration, from the ESCP Europe in Paris, and Master in Exercise Physiology from the Norwegian School of Sport Science Oslo, Norway.
Aleap, facilitate innovation and value creation by developing an ecosystem for health startups that allow ambitious entrepreneurs and companies to create new products better and faster.
Professor of Entrepreneurship, University of Stavanger
Tatiana Iakovleva holds a Professor of Entrepreneurship in Stavanger Business School, Stavanger Center for Innovation Research, University of Stavanger, Norway. She is a co-founder of Local Chapter of PI Norway.
Dr. Iakovleva’s research interests include entrepreneurial and innovative firm behaviour, social and responsible innovation and entrepreneurship, as well as factors affecting entrepreneurial intentions.
She is currently leading an international research project on Digitalization and Responsible Innovation across 6 countries, funded by Norwegian Research Council.
Tatiana received her PhD in Entrepreneurship and Organizational Management form Nord University (Norway) in 2008, she has Cand. Merc and Master of Science form Nord University and Master of International Business from Baltic Sate Technical University of St. Petersburg, Russia.
Professor and Senior Associate Dean, Católica-Lisbon School of Business and Economics
Pedro Oliveira is Professor and Senior Associate Dean at the Católica-Lisbon School of Business and Economics.
He is the founder and co-Project Leader of Patient Innovation: an open, global and non-profit online platform and community dedicated to the sharing of solutions developed by individuals afflicted with a health disorder, as well as by their caregivers (over 700 innovations were submitted and “medically screened” from a community of over 50.000 patients/caregivers from the 5 continents).
His research focus on open and user innovation and more specifically on the role of patients and caregivers in the development of solutions to help them cope with their diseases. Previously he was Academic Director of the LisbonMBA; director of the doctoral program in Technological Change and Entrepreneurship offered in partnership with Carnegie Mellon University; International Faculty Fellow at MIT Sloan; advisor to the Ministry of Science, Technology and Higher Education and Project Leader for Creative Commons PT.
Pedro received his Ph.D. in Operations, Technology and Innovation Management from The University of North Carolina at Chapel Hill, and both his M.Sc. and “licenciatura from IST (Lisbon). He also studied innovation at the Northwestern University’s Kellogg School of Management.
The Minister of Health and Care
The Minister of Health and Care is responsible for hospitals, health services in the municipalities, general health care and mental health.
CEO, Friend Software Corporation
Arne is a proven tech-entrepreneur with several successful exits to his name. Naval Academy, Arne served most of his seagoing service on Norwegian attack submarines. In 1995, Arne was hired by Det Norske Veritas (Classification Society – today DNV GL) and worked as Project Manager and Lead Auditor and headed prestigious projects in the Philippines, Panama and New York. In August 1998, Arne was headhunted by the Norwegian Shipowner’s Association as Head of Sections for Safety and Environmental issues and led their international lobbying efforts until he was requited by one of the member companies as chief commercial broker for a petrochemical ship transportation company, based in Houston, Texas. In 2002, Arne co-founded Accurate Equity, a FinTech SaaS and professional services company within equity based incentives design, accounting, valuation and disclosure, and bootstrapped it as CEO from scratch until 2013 where he took a board position and focused on the sale of the company. In 2015, the company was sold to Montagu Private Equity and merged with the share-plan and wealth management service of UBS, together with a portfolio of their 100 largest customers which combined today is the company Equatex. As investor and Chairman of MeaWallet, a FinTech SaaS infrastructure company enabling open loop mobile payment as a service (cloud based secure element, host card emulation and tokenization, adaptable front-end), Arne led the re-structuring of the business and in July 2016, he successfully sold the company to Seamless Distribution AB (Nasdaq; SEAM). Arne has an MBA from the Norwegian School of Economics (NHH) and the Norwegian University of Technology and Science as well as a degree in maritime law.
Heiko von der Leyen
CEO of Hannover Clinical Trial Center
Prof. Heiko von der Leyen, MD , managing director of HCTC, was trained in Pharmacology, Internal Medicine, and Cardiology at University of Hamburg, Hannover Medical School and Stanford University, CA, USA. Prof. von der Leyen was faculty member at the Division of Cardiovascular Medicine of Stanford University with research focus in cardiovascular gene therapy from 1995 to 1996. From 1998 to 2005 Prof. von der Leyen had several top management positions in biotechnology start-up companies with focus on the clinical development of advanced therapy medicinal products (tissue engineering, gene therapy, DNA medicine).
Medical Director, SAFER
Thomas Lindner is the Medical Director at the simulation centre SAFER in Stavanger and the Director of RAKOS I Helse Vest (The Regional Centre for Emergency Medical Research and Development) at the Stavanger University Hospital. Lindner has been a physician since 1995 and started his career as an anaesthesiologist at Stavanger University Hospital in 2001, since 2004 he is active as a physician in the helicopter emergency service (HEMS) in Stavanger. In 2015 Lindner completed his PhD thesis on survival after cardiac arrests outside the hospital in Rogaland. He was the head of the mobile stroke unit project from the Norwegian Air Ambulance Foundation.
Dr. Vishal Gulati is one of the Europe’s leading digital healthcare investors. Vishal is a qualified physician and chairman of the Digital Health Forum. Over the last decade he has championed deals across areas including diagnostics, devices & biotech. He is currently on the boards of LifeSum, Clue, Horizon Discovery plc, PushDr, Fluidic Analytics and Frameshift.
His previous investments include Napo Pharmaceuticals, Glenmark, Renovo, and Phagenesis. He has also held board positions at Psynova Neurotech, Bioscale and Enigma Diagnostics.
Previously, Vishal worked at Atlas Venture, The Wellcome Trust and Radiant Capital.
Morten Graugaard Døssing
Investment Director, Novo Seeds
Morten joined Novo Seeds in 2016 as Principal. He serves on the Board of Hoba Therapeutics, NMD Pharma and Merozyne Therapeutics.
Prior to joining Novo, Morten was Director of Corporate Development at H. Lundbeck A/S where he was involved in M&A, corporate strategy, BD&L, portfolio management and equity investments. While at Lundbeck Morten successfully led the acquisition of orphan neurology company Chelsea Therapeutics for 658 USD m and was involved in a range of other deals including the 1.8 USD Bn alliance with Otsuka Pharmaceuticals as well as equity investments and spinouts. Before Lundbeck, Morten worked as commercial manager in technology transfer to commercialize and establish new companies in biotech and medtech. Earlier in his career, Morten co-led the life science consulting practice at a boutique advisory firm in Copenhagen focusing on business development and management consulting.
CEO, MindUP – the Digital Health Incubator
Dan has been a leader in the global healthcare technology industry for over 15 years, with experience spanning Fortune 500 companies in the U.S. to Israeli startups. Prior to joining MindUP, Dan was CEO and President of Virtual Ports Inc., a company developing, manufacturing and marketing innovative products to improve laparoscopic surgery. Prior positions include General Manager (EndoTool Business Unit) and Director of Strategic Marketing for Hospira Worldwide, Inc., a global specialty pharmaceutical and medication delivery company, and senior positions at Johnson & Johnson (Ethicon and Ethicon EndoSurgery) and LifeWatch, Inc. Dan holds a Master’s in Business Administration, with Honors, from the University of Chicago Booth School of Business, and a Bachelor of the Arts, Cum Laude, in Economics and Business Administration from the University of Haifa, Israel.
MindUP, Haifa’s Digital Health Incubator is a joint venture of Medtronic, IBM, Pitango Venture Capital, Impact 1st Investments and Rambam Medical Center in collaboration with Israel Innovation Authority.
Chairman, Oslo Cancer Cluster
Henrik Lund leads the Board of Directors of Oslo Cancert Cluster and has been a board member for Oslo Cancer Cluster since 2008. Lund is an MD PhD from University of Oslo and received his post-doctoral training at UC San Francisco in lipidology. From 1994 to 2015 Lund had seversl management positions in the pharmaceutical industry. In 2005 – 2010 Lund served as VP of AstraZenecas Marketing Company clinical development group. He has also served as CEO and Chairman of the Board of several Norwegian biotech/life science companies. Lund is an independant strategic Life Science consultant with focus on biotech financing, management of IP/patents and now serves as CEO management for hire of Regenics AS, a marine biotech in Oslo.
General Manager, Roche Norway
Elizabeth Jeffords serves as the General Manager for Roche Norway, overseeing sales, marketing, clinical, medical, access, compliance, and regulatory activities for the Roche Norwegian affiliate in Oslo. She also serves on the Roche Personalised Healthcare Steering Committee. For the past 16 years, she served in Global and US roles for Roche and Genentech respectively, in access, policy, commercial operations, and in marketing strategy across the Roche portfolio of drugs, including 13 oncology medicines.
Anne Kjersti Fahlvik
Executive Director for Innovation, The Research Council of Norway
Anne K Fahlvik is the Executive Director for Innovation at The Research Council of Norway (Forskningsrådet).
Fahlvik holds a M.Pharm and a Ph.D/dr.philos in pharmacology from the University of Oslo.
She has 12 years of experience as an industrial scientist and from R&D management in pharmaceutical industry in Norway and the US and five years as CEO of a VC financed med-tech startup company.
M.D. And Researcher, Betanien hospital
Physician and researcher, Anita Kåss, is the developer of a hormonal medicine for rheumatoid arthritis, based on her PhD at the University of Oslo. The rights to the medicine are now owned by a Japanese pharmaceutical company and has the potential for billions in revenue. This is the largest licensing agreement made by a Norwegian hospital.
Anita lost her mother at the age of 13 to arthritis. At the same time she was awarded the Child of Achievement award from Princess Diana. Her mother´s illness spurred Anita to become a physician and pursue a career in the research of rheumatism with a focus in arthritis.
Her research studies have been presented in the groundbreaking categories in the largest rheumatology conferences.
She has received several national and international prizes within rheumatology, as well as many public and private grants. She has recently started up a company, Kaass, to develop innovative drugs.
Sigurd M. Paulsen
Nordic Co-Chair of 37 ºC Life Science Technology Conference & Exhibition
Sigurd M. Paulsen is an independent advisor and board member with experience from start-ups to business development of established companies and interests spanning from algorithms to hard-ware.
Up to 2016 Sigurd was Investment Director in Statoil Technology Invest (Statoil’s Corporate Venture). Statoil Technology Invest has holdings in 20 start-up/early phase companies and 6 seed funds. Here he was responsible for a number of investments in early stage oil technology and renewable energy companies and funds. Between 1986 and 2008, Sigurd held several senior position within in Statoil´s oil trading, corporate strategy, M&A and investments (in international private equity funds). Before joining Statoil, he worked in direct sales/wholesale in the IT, and fashion industries, and as well as agricultural industries in Norway, US and Germany. Sigurd holds a MSc in Finance from University of St.Gallen, Switzerland and has studied Business Law at University of California Los Angeles, USA
CEO, Norwegian Smart Care Cluster
Arild has a degree in economics and business administration (Siviløkonom) from Heriot-Watt University, Edinburgh. He has extensive sales & management experience as a manager, entrepreneur, and consultant in companies such as IBM, Datus (iSolutions), Metier, and Eskaler. He has since 2014 been the manager for the Health & Care Technology Incubator in Validé. Arild holds several board positions and is CEO for the Norwegian Smart Care Cluster program.
Huw Scott is the Chief Technical Officer for Astralution. Huw brings to the company a wealth of previous operational and engineering knowledge from the Medical industry, Aerospace Industry and Oil & Gas Industries (subsea technologies). His previous knowledge of unmanned systems and flight dynamics is of high value to the company and has stimulated many innovative ideas. His ability to understand technologies from across multiple industries serves the company well as we seek to draw together many current technologies into our solution packages for our end clients from varied sectors.
Partner, Betanien hospital
Dr. Kamilla Rolsted is co-founder and Partner at Sund Capital. Sund Capital is a specialized healthcare investment fund focused on Nordic based biotech opportunities. Kamilla has extensive experience from the healthcare industry both as scientist and in recent years from executive positions in publicly traded Zealand Pharma A/S and Bionor Pharma ASA.
Kamilla has been responsible for leading and defining corporate strategy, scouting for and evaluating assets and has participated in the negotiation of numerous agreements with pharmaceutical companies and academia. Kamilla is a certified pharmacist, holds a PhD in bioanalysis/DMPK from the University of Copenhagen and an EMBA from Copenhagen Business School.
Professor of Rheumatology, NOVA Medical School
Co-leader and Chief Medical Officer, Patient-Innovation Project. Helena Canhão is Full Professor at NOVA Medical School & National School of Public Health, Lisbon Portugal.
She is also Head of the EpiDoc Unit at CEDOC, the Chronic Diseases Research Centre at Nova Medical School.
She is Project leader and Chief Medical Officer of the Patient Innovation Project (https://patient-innovation.com/), Vice-President of Portuguese League Against Rheumatic Diseases (LPCDR), Vice- President of the Portuguese Society of Rheumatology (SPR).
Graduation, PhD and Habilitation in Medicine (Rheumatology) from the Lisbon School of Medicine, University of Lisbon. She also got a Master of Medical Sciences from Harvard School of Medicine, University of Harvard.
Enterprise Architect, Sykehuspartner HF
André is an Enterprise Architect in Sykehuspartner, the IT service provider to the South Eastern Norway Regional Health Authority (HSØ).
HSØ is the largest regional specialist healthcare thrust in Norway, with 80.000 employees serving 2,8 million citizens.
He has contributed to Medicloud since 2014. Medicloud is a concept to facilitate and accelerate innovations within ehealth and was awarded “2016 – project of the year” by IBM Norway. Medicloud is also part of C3 – centre for research-based innovation (SFI) funded by Norwegian National Research Council and the FIGI project at UIO.
André started out as a commercial pilot and flight instructor. Later he obtained a bachelor’s degree in avionics and a master of science (Sivilingeniør) in IT (signal and image processing) from the University of Stavanger. He has spent the last 18 years at the Norwegian Defence, Statoil ASA, and Sykehuspartner HF/HSØ. His focus areas is innovations, large-scale modern platforms and Information Assurance.
Nils Petter Oveland
CEO, Prometheus Medical Nordic
Dr. Nils Petter Oveland is a consultant at the Department of Anaesthesiology and Intensive Care, Stavanger University Hospital, Norway. Since 2007 he has been a medical crewmember of the air ambulance service in the southwest of Norway, responding to both medical and trauma emergencies. His area of expertise is point-of-care diagnostics, especially pre-hospital use of mobile ultrasound machines. In 2013 he finished his PhD looking at lung ultrasound detection of chest injuries. Based on his efforts, the national Air Ambulance Service of Norway has implemented point-of-care ultrasound into their helicopters and airplanes. Furthermore, he is the medical project manager of a new biomedical research center called Sandnes Education And Research Center (SEARCH) in the Stavanger region. Dr Oveland is an inventor, author of scientific papers, host of international ultrasound congresses/courses and international speaker, and he has received multiple public and private grants as well as being a two-times winner of the Poster Prize for best research at the London Trauma Conference in 2012 and 2014. In 2016 he started Prometheus Medical Nordic, an inventive medtech company providing emergency medical equipment and high-quality medical training courses for a wide audience; from the layperson to the healthcare professional.
Chief Commercial Offier, Friend Software Labs
Terje Gausel is an experienced business developer and project manager, with over 20 years’ experience from working with disrupting technologies within the Telecom, IT and Energy sector. As CEO in Kvantel AS from 2009 – 2015, he restructured and adapted the company to the rapid development within the IT-industry, which resulted in Kvantel to be one of the fastest growing telco companies in Norway at the time. Terje has been working with sales and business development for Friend Software Corporation since March 2016.
Ole Petter Ottersen
Rector, University in Oslo
Ole Petter Ottersen is a Norwegian physician and neuroscientist. Since 1992 he has worked as a professor of medicine at the University of Oslo. In 2009 he became the rector of the university of Oslo. Ottersen is researching the brain’s signal molecules and water channels. Ole Petter has published over 350 scientific articles on cell biology and neuroanatomy, with emphasis on signal transduction, synaptic transmission and brain edema formation. According to Google Scholar, Ottersen is cited over 34,000 times in scientific literature and is thus one of the most cited scientists internationally.
Senior Adviser, Ministry of Social and Health, Finland
Anssi Pulkkinen has been recently appointed to the Ministry of Social Affairs, Finnish Government as a Senior Consultant from his former post as the Strategic Director of Wellbeing and Health at Tekes, the Finnish Funding Agency for Innovation. He is currently working to build sustainable business models for secondary use of social and health data (for R&D&I, leading with data and clinical decision support). Mr. Pulkkinen has a strong background in business and strategic leadership positions in Big Pharma and Diagnostics. He holds a Master’s degree in Pharmacology in addition to an MBA from the Henley Business School (UK).
Head of Global Technologies, I-Tech Services at Subsea7
Adrian Dayani is the Head of Global Technologies, for I- Tech Services, the lifecycle support and management division of Subsea 7. He is current based out of Houston, Texas. Mr Dayani has over 20 years of technical management and business development experience developing intervention and asset management solutions to the energy industry (Power Generation/Electric Utility and Oil Industry) and defense sector. Adrian’s role at Subsea 7 is to assess market trends and opportunities, identifying, evaluating and managing the implementation of technologies that will give i-Tech Services a competitive advantage.
Britta Smedegaard Andersen
Project Director, NEXT- National Experimental Therapy
Britta Smedegaard Andersen is the project director for NEXT – National Experimental Therapy Partnership. Britta holds a Masters in Pharmaceutics from Denmark’s Farmaceutiske University.
NEXT aims to make Denmark a preferred country for early clinical testing of new drugs in patients. In particular, NEXT focuses on proof of concept trials, works to optimise all processes relating to the start-up and implementation of clinical trials, and optimises legal and statutory processes.
NEXT – National Experimental Therapy Partnership is a public-private partnership within clinical research consisting of the regions of Denmark, universities, twelve pharmaceutical companies and one GTS institute. Additionally, NEXT has several associated partners.
Ole Jacob Elle
Head of Technology Research, The Intervention Centre, Oslo University Hospital
Major scientific contributions include developments in a) Image guided surgery, Image navigation, Sensor control and haptic feedback in Robotic surgery and Biosensor development and monitoring b) has established a broad international network within image guided surgery, both academic
and industrial through participation and coordination of the contribution from The Intervention Centre, OUS as a partner in four EU-funded projects (ARISER-Augmented Reality in Surgery, SCath-Smart Catheterization, IIIOS-Integrated Intraoperative Imaging Operating System, I-SUR – Intelligent Surgical Robotics).
A strong national collaboration has been established with NTNU and Medical Technology at Sintef in image guided surgery.
Ole Jakob Elle has been committee member for several national seminars in medical technology as well as for Society for Minimally Invasive Technology (SMIT 2002) and is currently a board member of SMIT c) Awarded for papers in Journal of Physiological Measurement and Journal of Sensor Review. He is reviewer for IEEE International Conference on Robotics and Automation.
Managing Partner, Hadean Ventures
Dr. Walter Stockinger is co-founder and Managing Partner at Hadean Ventures, a pan-European life-science venture fund based in Oslo. Hadean Ventures invests into start-up companies, which develop patient focused healthcare products across all relevant technologies including devices, drugs, diagnostics and e-health with a strong focus on clinical efficacy.
His previous experiences include almost a decade of venture capital investing with a global VC fund, healthcare consulting at the Boston Consulting Group and post-doctoral research at Harvard University. Walter has a Master’s degree in Biochemistry and a PhD in Molecular Biology from the University of Vienna.
CEO, Ultimovacs AS
Øyvind Arnesen is the CEO at Ultimovacs AS, a company developing therapeutic cancer vaccines. He is a Medical Doctor (MD) with 10+ years of clinical experience and 10+ years of experience from pharma industry with positions as Medical Director Norway (Bristol-Myers Squibb), Medical Director and Head of Clinical Operations Nordic countries in Boehringer Ingelheim. Member of The National Commission for the Investigation of Research Misconduct in Norway. Board member of the Norwegian Pharmaceutical Industry Assoc.
Petter Risøe is the CEO and co-founder of Diffia, a digital health company aspiring to cut time hospital doctors and nurses spend on paperwork in half.
He is a former resident internal medicine at Akershus University Hospital, and a board member of the Norwegian Junior Doctor Association (Yngre legers forening).
Risøe also holds an MPH degree in Applied Statistics & Epidemiology from Yale University, and PhD from the University of Oslo on the innate immune response in sepsis.
Lars Johan Frøyland
Director Business Development, Sykehusinnkjøp HF
Lars-Johan Frøyland has been recently appointed to Sykehusinnkjøp HF as Director Business Development. From his former post as Chief Procurement Officer (CPO) at Western Norway Regional Health Authority (Helse Vest RHF) he holds 15+ years extensive experience in the area of public procurement and supply chain management for hospitals. He has been involved in several projects within the European Commission, serving as Director Healthcare in the EU funded PEPPOL-project. Back in 2014, he was member of a Commission to examine the national Norwegian rules on public procurement, appointed by the Norwegian Government. On behalf of the Ministry of Trade, Industry and Fisheries, Mr. Frøyland attends the Public Procurement Experts in the Health Sector – meetings organised by the European Commission. He holds a MBA in International Business from University of East London, and a Diploma in Management studies from European Collage of Business and Management, London.
Professor, University of Stavanger
Kjersti Engan holds a (B.E.) degree in electrical engineering from Bergen University College in 1994 and the Siv.Ing. (M.Sc.) and Dr.Ing. (Ph.D.) degrees in 1996 and 2000 respectively, both in electrical engineering from the University of Stavanger, Norway.
She is currently working as a professor with the department of Electrical Engineering and Computer Science at The University of Stavanger (UiS), Norway. She is also a part of the Biomedical data analysis group at UiS.
Engan’s research interests are signal and image processing, particularly Biomedical signal and image processing, analysis and classification. She is involved in several projects in collaboration with the local hospital and local companies in areas as; analysis, classification and segmentation in Cardiac MR on infarct patients, Brain MRI on dementia patients, analysis and classification on ECG of cardiac arrest patients, analysis and classification on ECG and ventilation signals of newborns, and real time estimation of compression quality during CPR using smartphone.
CEO, Laerdal Medical
Tore Laerdal is Chairman/CEO of Laerdal Medical, an international market leader in education and therapy solutions for resuscitation and patient care.
The company is a family company that has been headquartered in Stavanger since its beginning in 1940. I today have 1400 employees in 25 countries.
Mr Laerdal is furthermore Chairman of Laerdal Global Health, a not-for-profit company established to help reduce maternal and newborn mortality in low resource settings. He is also Executive Director of the Laerdal Foundation.
Jon H. Kaspersen
Research Director, SINTEF
Jon H Kaspersen has a PhD in turbulent flow characteristics. Kaspersen has since 1997 been employed by SINTEF. The first 10 years he was involved in research and development of guidance systems for minimal invasive surgery, health care information systems and telemedicine. Blood flow simulation (CFD) as well as fluid-structure interaction simulation was also important research topics.
From 2007 and up to recently, Kaspersen has been leading SINTEF Multiphase Flow Laboratory – the world largest laboratory of its kind. In March this year Kaspersen took on as Research Director for the Health Department at SINTEF Technology and Society.
Professor, University of Stavanger
Elisabeth Willumsen is a professor in social work at University of Stavanger (UiS). She has her background in clinical social work, master in special education and a PhD in public health. Her research and publications have focused on interprofessional education and collaboration/collaborative work and service user participation in welfare contexts, and additionally between academia and practice (practice research). Recently, the area of social innovation in public sector has become central to her research projects, which have received funding from EU and the Norwegian Research Council. Willumsen holds a Professor II position at Molde University College and a co-position at Centre of Innovation Research (UiS).
Managing Director and Founder, mediq Innovation Experts
Jan Wende is the founder and managing director of mediq Innovation Experts. mediq is a strategy and innovation consulting firm, specializing in strategy development and implementation for technology and services. Over the past 10 years, the firm has successfully introduced disruptive technologies and established new healthcare standards in a variety of segments. mediq‘s multidisciplinary team of consultants employ a strategy to completion approach and work in close collaboration with hospitals, doctors, and regulators to solve their clients‘ innovation challenges. The firm’s focus is primarily on start-ups but it is also regularly approached by multinationals with specific innovation challenges. The firm has offices in Frankfurt and Tel Aviv and partners in New York and London.
Research Director, SINTEF
Mats Carlin’s passion is creating novel high-tech products, services and start-ups. Currently he is heading 37 researchers within smart sensor systems at SINTEF, Scandinavia’s largest research institute. These smart sensor systems are a vital part of many medtech products and an enabler for the digital revolution we are experiencing.
Mats Carlin holds a MSc in electronics, a PhD in informatics and is the co-inventor on 7 patents and co-author of 15 research papers. Mats Carlin has 10 years of research experience at SINTEF working with industrial machine vision systems based on image analysis, artificial intelligence and data analysis, 5 years as CTO in a start-up company and 10 years as research director at SINTEF.
Mats Carlin is vice chairman of the board of SINTEF Technology Transfer Office that manages SINTEFs IP, spin-out and licensing activities, including our own venture fund of 209 MNOK. He has also been board member of a spin-off from SINTEF, GasSecure AS, from establishment to successful commercial exit at 500 MNOK. He currently heads the work with SINTEFs new digital research strategy.
Partner, Menon Economics
Erland Skogli holds a Master of Business Administration (MBA, France) with a specialization in strategy. He also holds a master of Economics and Political Science from the Netherlands and Norway, with a specialization in innovation. Erland has broad experience with working with and reviewing the industrial policy with in-depth analysis of the innovation within public and private sector. He also has significant experience from various employment policy analysis.
Erland has a many years of experience working with strategical processes, both as adviser and leader. Erland also has industry specific expertise in the areas of trade, ICT and consumer service.
Erland has previously held management positions in the analysis field for NHO and Virke. He has also worked as a strategic adviser for Booz & Co (now PWC), Ernst & Young and inFuture. He started his carrier as a scientist in STEP-Group.
Dr. Malcolm G. Russel
Chief Executive Officer, Prometheus Medical Ltd